ArticleBiochemistry and biophysics reports2026
The tetraspanin CD81 regulates the metastasis-promoting function of the osteosarcoma secretome.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a highly aggressive malignancy in which pulmonary metastasis remains the leading cause of mortality. Tumor cell-derived secretome, comprising extracellular vesicles and soluble factors, has been implicated in cancer progression and metastatic dissemination; however, the mechanisms regulating its functional properties remain incompletely understood. CD81, a member of the tetraspanin family, is widely recognized as a marker of extracellular vesicles and has been associated with tumor progression and metastasis. In this study, we investigated the role of CD81 in regulating the metastasis-promoting function of the osteosarcoma-derived secretome. Secretome was collected from 143B wild-type osteosarcoma cells and 143B CD81-knockout cells and applied to in vitro and in vivo models. Secretome derived from wild-type cells significantly enhanced tumor cell proliferation, migration and invasion, whereas secretome derived from CD81-knockout cells showed markedly attenuated effects. In endothelial cells, secretome from wild-type cells promoted angiogenic activity, which was markedly attenuated in CD81-knockout cells, indicating a role in modulating tumor-endothelial interactions. In vivo, repeated administration of secretome from wild-type cells induced the accumulation of CD11b-positive and S100A8/A9-positive cells in the lung and significantly increased pulmonary metastasis following tumor cell injection. In contrast, these effects were substantially reduced in mice treated with secretome from CD81-knockout cells. These findings identify CD81 as a tumor-cell-intrinsic determinant of whether the osteosarcoma secretome itself acquires metastasis-promoting bioactivity, distinct from previously identified downstream secreted effectors, and suggest that CD81 may represent a therapeutic target acting across both tumor and microenvironmental compartments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.